Probiotic recolonisation therapy
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia . The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides , Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus , and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli , at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
1. A method for treating a gastrointestinal symptom in a subject in need thereof, said subject having autism and said gastrointestinal symptom, and said method comprising administering to said subject an amount of a pharmaceutical composition effective for treating said gastrointestinal symptom, wherein said pharmaceutical composition comprises a viable, non-pathogenic Clostridium sp, wherein said method does not require the removal of a portion of said subject's existing enteric microflora via orthostatic lavage prior to said administration of said pharmaceutical composition.
2. The method of claim 1 , wherein said pharmaceutical composition further comprises a viable, non-pathogenic Bacteroides sp.; a viable, non-pathogenic Escherichia coli ; or both.
3. The method of claim 2 , wherein said viable, non-pathogenic Clostridium sp., Bacteroides sp., or Escherichia coli , is from a culture.
4. The method of claim 1 , wherein said gastrointestinal symptom is selected from the group consisting of irritable bowel syndrome, chronic persistent diarrhoea, diarrhoea, flatulence, constipation, and alternating constipation/diarrhoea.
5. The method of claim 1 , wherein said pharmaceutical composition is also effective for treating a symptom of said autism.
6. The method of claim 1 , wherein said subject exhibits one or more symptom improvements selected from the group consisting of reduced repetitive action, sleeping through the night, increased eye contact, and progressively increased word power.
7. The method of claim 1 , wherein said pharmaceutical composition comprises no viable Fusobacterium, Propionibacterium, Lactobacillus, Ruminococcus, Gemmiger, Desulfomonas, Peptostreptococcus, Bifidobacterium , or any combination thereof.
8. The method of claim 1 , wherein said pharmaceutical composition comprises a plurality of viable, non-pathogenic Clostridium spores.
9. The method of claim 1 , wherein said viable, non-pathogenic Clostridium sp. is selected from the group consisting of Clostridium absonum, Clostridium argentinense, Clostridium baratii, Clostridium bifermentans, Clostridium botulinum, Clostridium butyricum, Clostridium cadaveris, Clostridium camis, Clostridium celatum, Clostridium chauvoei, Clostridium clostridioforme, Clostridium cochlearium, Clostridium difficile, Clostridium fallax, Clostridium felsineum, Clostridium ghonii, Clostridium glycolicum, Clostridium haemolyticum, Clostridium hastiforme, Clostridium histolyticum, Clostridium indolis, Clostridium innocuum, Clostridium irregulare, Clostridium limosum, Clostridium malenominatum, Clostridium novyi, Clostridium oroticum, Clostridium paraputrificum, Clostridium perfringens, Clostridium piliforme, Clostridium putrefaciens, Clostridium putrificum, Clostridium ramosum, Clostridium sardiniense, Clostridium sartagoforme, Clostridium scindens, Clostridium septicum, Clostridium sordellii, Clostridium sphenoides, Clostridium spiroforme, Clostridium sporogenes, Clostridium subterminale, Clostridium symbiosum, Clostridium tertium, Clostridium tetani, Clostridium welchii , and Clostridium villosum.
10. The method of claim 1 , wherein said viable, non-pathogenic Clostridium sp. is selected from the group consisting of Clostridium bifermentans, Clostridium innocuum, Clostridium ramosum , and Clostridium butyricum.
11. The method of claim 1 , wherein said pharmaceutical composition further comprises a viable, non-pathogenic Collinsella sp.
12. The method of claim 11 , wherein said viable, non-pathogenic Collinsella sp. is Collinsella aerofaciens.
13. The method of claim 1 , wherein said method comprises administering an antibiotic, an acid suppressant, an antacid, an H2 antagonist, a proton pump inhibitor or a combination thereof.
14. The method of claim 13 , wherein said antibiotic is selected from the group consisting of vancomycin, rifampicin, and nitroimidazole, chloramphenicol, and Septrin.
15. The method of claim 1 , wherein said pharmaceutical composition is formulated as an enteric coated capsule, an enteric coated microcapsule, a lyophilized powder, a naso-duodenal infusion, or for delivery in the form of an enema or a colonoscopic infusion.
16. The method of claim 1 , wherein said pharmaceutical composition is added to a food, a food additive, a dairy-based product, a soy-based product or a derivative thereof, a jelly, or a yogurt.
17. The method of claim 1 , wherein said pharmaceutical composition is administered three times daily (tid).
18. The method of claim 1 , wherein said pharmaceutical composition comprises between about 10 9 and about 10 11 viable, non-pathogenic bacteria.
19. The method of claim 1 , wherein said pharmaceutical composition is administered orally.